Log in to your Inderes Free account to see all free content on this page.
Biovica International
1.94
SEK
+8.87 %
BIOVIC B
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Less than 1K followers
+8.87%
-3%
-29.2%
-21.77%
-17.8%
-26.65%
-94.65%
-82.91%
-82.55%
Biovica International is a pharmaceutical company that focuses its research on cancer treatments. The company is developing methods for measuring cell proliferation, where the test is taken via blood samples. The tests analyze the risk for the development of the enzyme thymidine kinase, an enzyme that is linked to tumor growth. The main area of focus is within treatment of breast cancer. The company was founded in 2008 and is headquartered in Uppsala.
Read moreMarket cap
189.71M SEK
Turnover
56.47K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Financial calendar
13.3.
2025
Interim report Q3'25
19.6.
2025
Annual report '25
ShowingAll content types
Agreement signed with US insurance giant and expanded market
Biovica CLIA Lab achieves New York State permit that opens the entire US market
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio